The PMPRB protects and informs Canadians by ensuring that
the prices of patented medicines sold in Canada are not excessive and by
reporting on pharmaceutical trends.
Spending by Canadian public drug plans increased by an average of 2.0% in 2013/14, reversing a multi-year trend of low or negative growth.
Find out more…
Provincial generic-drug pricing policies and the efforts of
the pan-Canadian Pharmaceutical Alliance have played a key role in reducing
generic drug prices in Canada; however, prices remain above international
The PMPRB’s three-year Strategic Plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of a sustainable health system.
The Honourable Jane Philpott, Federal Minister of Health, has tabled the 2014 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.
Reducing brand-name prices to generic levels would offer
sizable savings in private plans.
This first study in the new NPDUIS private drug plan series
explores the evolving generic market in private plans.